Publications

Export 54 results:
Auteur Title Type [ Année(Asc)]
Filtres: Auteur is Judes Poirier  [Enlever les filtres]
2021
Gonneaud J, Baria AT, Binette APichet, Gordon BA, Chhatwal JP, Cruchaga C, Jucker M, Levin J, Salloway S, Farlow M et al..  2021.  Accelerated functional brain aging in pre-clinical familial Alzheimer's disease.. Nat Commun. 12(1):5346.
Picard C, Nilsson N, Labonte A, Auld D, Rosa-Neto P, Ashton NJ, Zetterberg H, Blennow K, Breitner JCS, Villeneuve S et al..  2021.  Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease.. Alzheimers Dement.
Nilsson NIV, Picard C, Labonte A, Köbe T, Meyer P-F, Villeneuve S, Auld D, Poirier J.  2021.  Association of a Total Cholesterol Polygenic Score with Cholesterol Levels and Pathological Biomarkers across the Alzheimer's Disease Spectrum.. Genes (Basel). 12(11)
Binette APichet, Theaud G, Rheault F, Roy M, D Collins L, Levin J, Mori H, Lee JHong, Farlow MRhys, Schofield P et al..  2021.  Bundle-specific associations between white matter microstructure and Aβ and tau pathology in preclinical Alzheimer's disease.. Elife. 10
Tremblay-Mercier J, Madjar C, Das S, Binette APichet, Dyke SOM, Etienne P, Lafaille-Magnan M-E, Remz J, Bellec P, D Collins L et al..  2021.  Open science datasets from PREVENT-AD, a longitudinal cohort of pre-symptomatic Alzheimer's disease.. Neuroimage Clin. 31:102733.
Köbe T, Binette APichet, Vogel JW, Meyer P-F, Breitner JCS, Poirier J, Villeneuve S.  2021.  Vascular risk factors are associated with a decline in resting-state functional connectivity in cognitively unimpaired individuals at risk for Alzheimer's disease: Vascular risk factors and functional connectivity changes.. Neuroimage. 231:117832.
2019
Fiocco AJ, D'Amico D, De Beaumont L, Poirier J, Lupien S.  2019.  Association between BDNF Polymorphism and Hypothalamic-Pituitary-Adrenal Activity in Later Adulthood.. Gerontology. :1-7.
Miron J, Picard C, Labonte A, Auld D, Breitner JCS, Poirier J.  2019.  Association of PPP2R1A with Alzheimer's disease and specific cognitive domains.. Neurobiol Aging. 81:234-243.
Miron J, Picard C, Lafaille-Magnan M-E, Savard M, Labonte A, Breitner JCS, Rosa-Neto P, Auld D, Poirier J.  2019.  Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation.. Alzheimers Dement. 15(7):951-960.
Liebsch F, Kulic L, Teunissen C, Shobo A, Ulku I, Engelschalt V, Hancock MA, van der Flier WM, Kunach P, Rosa-Neto P et al..  2019.  Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression.. Nat Commun. 10(1):2240.
Chertkow H, Borrie M, Whitehead V, Black SE, Feldman HH, Gauthier S, Hogan DB, Masellis M, McGilton K, Rockwood K et al..  2019.  The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study.. Can J Neurol Sci. 46(5):499-511.
Meyer P-F, Savard M, Poirier J, Morgan D, Breitner JCS.  2019.  Hypothesis: cerebrospinal fluid protein markers suggest a pathway toward symptomatic resilience to AD pathology.. Alzheimers Dement. 15(9):1160-1171.
Meyer P-F, Tremblay-Mercier J, Leoutsakos J, Madjar C, Lafaille-Maignan M-É, Savard M, Rosa-Neto P, Poirier J, Etienne P, Breitner JCS.  2019.  INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.. Neurology. 92(18):e2070-e2080.
Lleó A, Alcolea D, Martínez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER et al..  2019.  Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.. Alzheimers Dement. 15(6):742-753.
Meyer P-F, Labonte A, Rosa-Neto P, Poirier J, Breitner JCS.  2019.  No apparent effect of naproxen on CSF markers of innate immune activation.. Ann Clin Transl Neurol. 6(6):1127-1133.
Picard C, Poirier A, Bélanger S, Labonte A, Auld D, Poirier J.  2019.  Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer's disease: A genetic and proteomic multi-cohort study.. PLoS One. 14(8):e0220254.

Pages